Developmental Therapeutics Program

One Dose Mean Graph

NSC: 762687 / 1	Conc: 1.00E-5 Molar	Test Date: Nov 28, 2011
Experiment ID: 1111OS67		Report Date: Oct 02, 2012

Panel/Cell Line	Growth Percent
Leukemia	
CCRF-CEM	83.82
HL-60(TB)	89.31
K-562	71.88
MOLT-4	104.89
RPMI-8226	97.68
SR	72.93
Non-Small Cell Lung Cancer	
A549/ATCC	85.87
EKVX	107.62
HOP-62	106.43
HOP-92	113.06
NCI-H226	103.99
NCI-H23	104.68
NCI-H322M	102.76
NCI-H460	98.55
NCI-H522	83.27
Colon Cancer	
COLO 205	114.48
HCC-2998	103.60
HCT-116	94.30
HCT-15	76.69
HT29	96.84
KM12	75.04
SW-620	100.93
CNS Cancer	
SF-268	84.73
SF-295	104.80
SF-539	99.31
SNB-19	104.61
SNB-75	92.76
U251	105.33
Melanoma	
LOX IMVI	78.40
MALME-3M	99.64
M14	98.78
MDA-MB-435	98.66
SK-MEL-2	101.86
SK-MEL-28	124.62
SK-MEL-5	92.98
UACC-257	100.75
UACC-62	93.14
Ovarian Cancer	
IGROV1	103.33
OVCAR-3	114.41
OVCAR-4	113.72
OVCAR-5	96.45
OVCAR-8	97.15
NCI/ADR-RES	107.28
SK-OV-3	97.95
Renal Cancer	
786-0	83.48
A498	100.98
ACHN	102.13
CAKI-1	85.67
RXF 393	118.61
SN12C	102.48
TK-10	100.27
UO-31	76.49
Prostate Cancer	
PC-3	95.41
DU-145	95.08
Breast Cancer	
MCF7	102.09
MDA-MB-231/ATCC	104.12
HS 578T	111.23
BT-549	57.06
T-47D	106.45
MDA-MB-468	103.81
Mean	97.41
Delta	40.35
Range	67.56

Mean Growth Percent - Growth Percent